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ORIGINAL ARTICLE
Sepsis remains a poorly understood entity that
accounts for considerable morbidity and mortality
in critical care units.1–8 The host factors that con-
tribute to the development and treatment of sep-
sis are perhaps the key element to understanding
the pathophysiology of severe sepsis and septic
shock.1,9–12 The relative amounts of proinflam-
matory or anti-inflammatory response produced
in response to septic stimuli are of substantial
clinical relevance. There is convincing evidence of
a prolonged and at times rather profound sys-
temic anti-inflammatory state, a state of relative
immunosuppression, that follows the onset of
sepsis.13–16 Although the precise molecular expla-
nation for sepsis-induced immunosuppression is
incompletely understood, a considerable number
of immunologic events have been described in this
clinical situation.17–19 An important event among
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p < 0.001); there was no difference between ulinastatin-treated (52 ± 13.9; p > 0.05) and non-treated PPAH
mice (50.4 ± 16). The thymus gland cell count reduced significantly in PPAH mice (8.1 ± 4.7 × 107) compared
to control mice (12.8 ± 6.6 × 107; p < 0.01), and immunofluorescence analysis demonstrated that the reduced
cells were mostly CD4+ CD8+, in contrast to the increase in CD4+ CD8− cells. There was no difference in cell
count between ulinastatin-treated (8.7 ± 4.9 × 107) and non-treated PPAH mice (7.4 ± 4.6 × 107; p > 0.05).
Caspase 3-mediated apoptosis was not detectable in control mice in contrast to the pronounced manifestation
in PPAH mice.
Conclusion: PPAH-induced sepsis has a high mortality that is related to lymphocyte apoptosis. Ulinastatin
alone does not significantly reduce caspase 3-mediated lymphocyte apoptosis. [J Formos Med Assoc 2007;
106(2):97–104]
Key Words: Aeromonas hydrophilia, apoptosis, caspase 3, protease inhibitor ulinastatin, sepsis
©2007 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Departments of 1Pediatrics, 3Pediatric Surgery and 4Pathology, China Medical University Hospital, Taichung, Taiwan, and 2Department of
Emergency and Critical Care Medicine, Surugadai Nihon University Hospital, Tokyo, Japan.
Received: February 3, 2006
Revised: August 2, 2006
Accepted: September 5, 2006
*Correspondence to: Dr Kuo-Juei Lin, Department of Pediatric Surgery, China Medical University Hospital,
2 Yuh Der Road, Taichung, Taiwan.
E-mail: bais@ms49.hinet.net
B.H. Su, et al
98 J Formos Med Assoc | 2007 • Vol 106 • No 2
these is excessive lymphocyte apoptosis.18–20 Pro-
tease inhibitors are known to prevent apoptosis
in vitro.21,22 On December 26, 2004, a giant earth-
quake in Southeast Asia triggered a deadly tsunami
across the Indian Ocean. A major problem asso-
ciated with the severely injured victims was sig-
nificant contamination and the microbiologic
assessment identified a variety of common path-
ogens, including Aeromonas species.23 The most
common Aeromonas species responsible for human
infection is protease-positive Aeromonas hydrophilia
(PPAH).24 These organisms are found in seawater,
sewage and in soil, produce multiple proteases
and cause severe infection and sepsis.25 Various
studies suggest that this pathogen causes mortal-
ity in immunocompromised hosts.26,27 The spec-
trum of human diseases caused by A. hydrophilia
includes gastroenteritis, cellulitis, necrotizing fas-
ciitis, meningitis, bacteremia and peritonitis.24 The
aim of this study was to determine the effect of
the protease inhibitor ulinastatin on survival and
lymphocyte apoptosis in sepsis induced by PPAH.
Materials and Methods
Animals, bacteria inoculation, and
experiment design
Breeder male mice of the C57BL/6J strain (6–8
weeks old, 15–20 g) were purchased from the Na-
tional Laboratory Animal Breeding and Research
Center, Taipei, Taiwan. They were housed in a
germ-free environment with excess rodent chow
and water in our animal care facility controlled
in temperature, humidity, and light (7:00–19:00).
Mice were housed for at least 3 days before ma-
nipulations. The animals were raised and cared
for according to the guidelines of the Guide for
the Care and Use of Laboratory Animals of Taiwan.
The study was approved by the institutional review
board of China Medical University Hospital.
PPAH was isolated clinically at the National
Cheng-Kung University Hospital, Taiwan. These
microorganisms were cultured in 2× yeast extract-
tryptan medium broth. To prepare the bacteria
for injection into mice, the bacteria strain was 
inoculated into the medium, grown overnight at
37°C with continuous shaking to reach 108 to
109/mL, then subcultured into a new medium in
1% for 3 hours. The number of bacteria was deter-
mined by turbidimetric assay. The cell density was
adjusted to 4 × 106 colony forming units (cfu) per
0.5 mL sterile phosphate buffered saline (PBS).
Beginning at the time indicated, 10 mice were
randomly allocated to intraperitoneal injection of
0.5 mL sterile PBS as control; 20 mice were ran-
domly allocated to intraperitoneal injection of
0.5 mL PPAH bacteria to induce sepsis, prior to
subjecting them to PBS or ulinastatin treatment.
After 30 minutes, control mice received an addi-
tional intraperitoneal injection of 0.5 mL sterile
PBS, 10 PPAH mice were intraperitoneally injected
with 0.5 mL sterile PBS (non-treated PPAH mice),
and the remaining 10 PPAH mice were treated with
intraperitoneal injection of ulinastatin (10,000 U/
kg) (ulinastatin-treated PPAH mice). Ulinastatin
was purchased from Mochida Pharm. Co. Ltd.
Animals were defined as mortality and were killed
if they demonstrated any of the following char-
acteristics: a moribund state, lateral recumbency,
and/or hypothermia (rectal temperature < 32°C).
All surviving animals were killed at 24 hours.
Measurement of thymus weight, cell 
count and magnitude of apoptosis
At the time of euthanasia, the thymus was re-
moved and weighed using a balance with an ac-
curacy to 0.0001 g. The cell count was measured
with a hematocytometer as previously described
by Lin et al.28 Mean values obtained represent
data of triplicates from each separate experi-
ment. The magnitude of lymphocyte apoptosis
in thymus was assessed by annexin V staining
with flow cytometry (FACScan; Becton Dickinson,
Mountain View, CA, USA), described previously
by Hotchkiss et al.29
Immunofluorescence analysis of 
thymocyte subsets
The following technique was adapted from that
described by Wang et al.30 CD3, CD4 and CD8
surface markers were used for determination of
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the subclassification of thymocytes. Stained thy-
mocytes were analyzed by flow cytometry. Cyto-
fluorometric analysis was performed on the
lymphocyte fraction as determined by side scatter
(SSC) and forward scatter (FSC) with laser excita-
tion set at 488 nm. A computer system (Cell Quest,
BD Biosciences) was used for data acquisition
and analysis.
Immunohistochemistry detection of caspase 3
The harvested thymus was placed in 10% neutral
buffered formalin. Caspase 3 immunoactivity of
thymocytes was detected by immunohistochem-
ical evaluation as previously described by Forkert
with minor modifications.31,32
Statistical analysis
Survival was analyzed by the χ2 test. Thymus
weight, cell counts and magnitude of lymphocyte
apoptosis were analyzed by Student’s t test. Results
are expressed as mean ± standard deviation. Stati-
stical significance was defined as p < 0.05.
Results
Experimental sepsis
Experimental sepsis was confirmed in all PPAH
mice by evidence of positive blood culture of 
A. hydrophilia or clinical signs of lateral recum-
bency and/or hypothermia.
Ulinastatin cannot increase survival in
PPAH sepsis
There was a significant difference in survival 24
hours after intraperitoneal injection between
PBS controls (100%) and all PPAH mice (35%;
p < 0.001), but no significant difference between
non-treated (30%) and ulinastatin-treated PPAH
mice (40%) (Figure 1).
Ulinastatin cannot significantly reduce
lymphocyte apoptosis in thymus in 
PPAH sepsis
The mean thymus weight decreased more signifi-
cantly in PPAH mice (51.1 ± 15 mg) compared to
controls (69.7±14 mg; p<0.001), but there was no
significant difference in thymic atrophy between
ulinastatin-treated (52 ± 13 mg) and non-treated
PPAH mice (50.4 ± 16 mg). Histologic examina-
tion of thymus revealed that the boundaries of
the cortex and medulla were well defined in con-
trol mice, and that tissue destruction in PPAH mice
was mostly located in the cortex of the thymus
(picture not shown).
The thymus gland cell count was significantly
lower in PPAH mice (8.1 ± 4.7 × 107) compared to
controls (12.8 ± 6.6 × 107; p < 0.01). The cell count
of ulinastatin-treated PPAH mice was higher (8.7±
4.9 × 107), but not significantly more so than that
of non-treated PPAH mice (7.4 ± 4.6 × 107). There
was a significantly higher percentage of lym-



















Figure 1. Survival rate of control and all protease-positive Aeromonas hydrophilia septic mice, PPAH(all). PPAH(US–),
non-treated PPAH mice; PPAH(US+), ulinastatin-treated PPAH mice. *p vs. control group (χ2 test).
compared to controls (25.9±15.9%; p<0.001), but
ulinastatin-treated PPAH mice did not show reduc-
tion in lymphocyte apoptosis (52.5±14.7%) com-
pared to non-treated PPAH mice (53.5±14.1%)
(Figure 2).
Immunofluorescence analysis demonstrated
a significant reduction in CD4+ CD8+ cells in the
PPAH mice compared to controls (p < 0.01), in
contrast to the significant increase in CD4+ CD8−
cells (p < 0.01) (Figure 3).
Ulinastatin cannot reduce caspase 
3-mediated lymphocyte apoptosis
Immunohistochemical evaluation of thymus did
not detect caspase 3 activity in controls; however,
there was pronounced manifestation of caspase 3
activity in all PPAH mice, especially in the expired
mice (Figure 4).
Discussion
A. hydrophilia is an important enteropathogen,33
commonly found in contaminated wounds.34
It has been shown to be resistant to first gen-
eration cephalosporins.23 The pathogenecity of 
A. hydrophilia may involve several extracellular
enzymes, including hemolysin, enterotoxin and
protease.25,35,36 The proteolytic enzymes excreted
by A. hydrophilia play an important role in the 
invasiveness and establishment of infection by
overcoming initial host defenses.37 In our current
study, we demonstrated that experimental sepsis
induced by intraperitoneal injection of PPAH 
in mice caused a high mortality rate. The thymic
atrophy seen in septic mice was caused by lym-
phocyte apoptosis. The apoptosis mostly occurred
in CD4+ CD8+ cells. In contrast to the decrease in
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Figure 2. Percentage of apoptosis in thymus of
control and all protease-positive Aeromonas 
hydrophilia septic mice, PPAH(all). PPAH(US−),
non-treated PPAH mice; PPAH(US+), 
ulinastatin-treated PPAH mice. *p vs. control




























Figure 3. Thymocyte subsets of control 
and all protease-positive Aeromonas 
hydrophilia septic mice, PPAH(all). 
PPAH(US−), non-treated PPAH mice;
PPAH(US+), ulinastatin-treated PPAH mice.
*p < 0.01, †p < 0.005, ‡p < 0.001 vs. control
group (Student’s t test).
CD4+ CD8+ cells, there was an increase in CD4+
CD8− cells. CD4+ CD8+ cells are immature T-cells
located mainly in the cortex of thymus. CD4+
CD8− cells are more mature and are located in the
medulla of thymus. The significant decrease in
CD4+ CD8+ cells is compatible with the phe-
nomenon that thymic atrophy in sepsis mostly
occurred at the cortex. The increase in CD4+ CD8−
cells implied that the activation of T lympho-
cytes was a part of the host immune response
after A. hydrophilia stimulation. In sepsis, antigen
presentation and expression of monocyte class II
major histocompatibility complex may activate
Th cells.38,39 Although we did not evaluate the 
T cell early-activation marker CD69,40 our finding
that CD4+ CD8− cells increased in PPAH mice
suggests that there is a significant increase in acti-
vated T cells in sepsis. This is compatible with
the finding that bacteremia, an initial sepsis
event, promotes lymphocyte activation and pro-
duction of Th1 cytokine, and, subsequently, en-
hanced lymphocyte activation and proliferation
leads to enhanced lymphocyte apoptosis and
immunosuppression.41
Ulinastatin, a protease inhibitor, is an acidic
glycoprotein discovered by Bauer and Reich in
human urine.42 It has been reported to be effective
in the treatment of pancreatitis,43 hemorrhagic
shock, traumatic shock, anaphylactoid shock, en-
dotoxin shock and septic shock.44 The confirmed
effects of ulinastatin are inhibition of cytokine
production,45 inhibition of tissue thromboplas-
tine secretion from leukocytes,46 and reduction
in lymphocyte apoptosis.22 Either antiretroviral
agent or ulinastatin was used as protease in-
hibitor, both were shown to inhibit lymphocyte
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Figure 4. Immunohistochemical detection of caspase 3 activity in thymus. (A) Caspase 3 activity is undetectable in 
control mice. Pronounced manifestation of caspase 3 activity (arrows) are detected in PPAH septic mice: (B) treated with
ulinastatin; (C) not treated with ulinastatin; and (D) especially in the expired mice (magnification, 400×).
apoptosis.21,22 These studies reported that despite
no intrinsic antibacterial effects, protease inhibitor
decreased the number of bacteria in blood.21,24
Reduction in endotoxin levels and activation of
leukocyte phagocytosis have also been reported.44
In our current study, we were unable to show
that ulinastatin improves survival and reduces
apoptosis in experimental sepsis induced by PPAH
bacteria. This result is in contrast to previous
studies, which reported improved survival and
inhibition of apoptosis in experimental sepsis with
protease inhibitors.21,22,43
The weight of the thymus decreased signifi-
cantly in all PPAH septic mice compared with con-
trol mice. This indicates that ulinastatin did not
effectively suppress apoptosis in PPAH-induced
experimental sepsis. This result was confirmed by
the results of an immunohistochemical study on
thymus, which showed that apoptosis via the cas-
pase 3-mediated pathway in PPAH septic mice was
not reduced by ulinastatin treatment. Apoptosis
is affected through an intracellular cascade of cys-
teine proteases known as caspases.47,48 Activation
of caspase 3, the final effector caspase which tar-
gets the DNA nuclease, is responsible for the char-
acteristic nuclear degradation of apoptosis.49 Our
study implies that the effect of ulinastatin on in-
hibition of caspase 3-mediated apoptosis was
not as effective as originally thought.
In conclusion, PPAH-induced sepsis has a high
mortality that is related to lymphocyte apoptosis;
the protease inhibitor ulinastatin alone cannot
significantly reduce the caspase 3-mediated lym-
phocyte apoptosis. The results of this study sug-
gest several possibilities. Assuming that ulinastatin
is a highly effective and nonselective inhibitor of
protease activity, one would expect that the drug
would cripple neutrophils and other immune cells
that rely on protease activity to eliminate bacterial
pathogens. As such, it is possible that immune
inhibition by the protease inhibitor contributes
to the observed lethality in the ulinastatin-treated
PPAH group. This possibility is supported by
previous investigations.50 Another explanation is
that ulinastatin does not effectively inhibit one
or more of the PPAH-associated proteases, either
due to inadequate dosing or reduced potency for
one or more proteases. This hypothesis warrants
further study to clarify whether the effect of ulinas-
tatin is only specific to certain proteases. Another
possible explanation is that protease release is
not essential for the toxicity of the organism in
study design. Although PPAH is an important
enteropathogen,33 introduction of the bacteria
by way of the peritoneum, rather than in a skin
wound, may obviate the requirement of proteases
to facilitate the dissemination of infection. Finally,
it is possible that the proteases facilitate early 
invasion of the organism (i.e. within 30 minutes),
after which other mechanisms become more 
important. Thus, our study design (i.e. adminis-
tration of the protease inhibitor 30 minutes after
the onset of infection) provides minimal insight
into the role of proteases during the early phase
of infection. Based upon the established potency
and pharmacologic properties of ulinastatin, pre-
treatment with ulinastatin and adequate dosing
thereafter would provide more definite support
for the conclusion that proteases are not essential
for the toxicity of PPAH. Alternatively, a protease
negative variant of the bacteria might be helpful
in further study.
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